Cite
1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A.
MLA
Gadgeel, S. M., et al. “1361P Alectinib for Treatment-Naïve Advanced ALK+ NSCLC Selected via Blood-Based NGS: Updated Analyses of Outcomes, Circulating Tumour (Ct)DNA and Biomarker Subgroups from BFAST Cohort A.” Annals of Oncology, vol. 34, Oct. 2023, pp. S782–83. EBSCOhost, https://doi.org/10.1016/j.annonc.2023.09.2394.
APA
Gadgeel, S. M., Mok, T. S. K., Peters, S., Nadal, E., Han, J.-Y., Alatorre Alexander, J. A., Leighl, N., Sriuranpong, V., Pérol, M., Castro, G. D., de Marinis, F., Tan, D. S. W., Paul, S., Assaf, Z. J., MacLennan, M., Lohmann, T. O., Slade, M., Mathisen, M. S., Bhagawati-Prasad, V., & Dziadziuszko, R. (2023). 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A. Annals of Oncology, 34, S782–S783. https://doi.org/10.1016/j.annonc.2023.09.2394
Chicago
Gadgeel, S.M., T.S.K. Mok, S. Peters, E. Nadal, J-Y. Han, J.A. Alatorre Alexander, N. Leighl, et al. 2023. “1361P Alectinib for Treatment-Naïve Advanced ALK+ NSCLC Selected via Blood-Based NGS: Updated Analyses of Outcomes, Circulating Tumour (Ct)DNA and Biomarker Subgroups from BFAST Cohort A.” Annals of Oncology 34 (October): S782–83. doi:10.1016/j.annonc.2023.09.2394.